English
Specials
    Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    Sansaar
    HomeNewsGepowerindia

    Jump to
    • We are planning 6-8 new launches this fiscal yr: Alembic Pharma

      We are planning 6-8 new launches this fiscal yr: Alembic Pharma

      Speaking to CNBC-TV18 Pranav Amin, Managing Director of Alembic Pharmaceuticals, said that good Q1 numbers were led by international business. Sales of its anti-psychotic drug Abilify was one of the reasons the company saw higher sales, he said.

    • Alkem's brush with Germany may not hit profit, revenue:Prabhudas

      Alkem's brush with Germany may not hit profit, revenue:Prabhudas

      There is growing harmonisation between leading regulators across the world and WHO is taking note of the observations made by US FDA on pharma companies everywhere, says Surajit Pal, pharma analyst at Prabhudas Lilladher.

    • EBITDA margin came off unusually high base: Alembic Pharma

      EBITDA margin came off unusually high base: Alembic Pharma

      In an interview with CNBC-TV18‘s Ekta Batra and Reema Tendulkar, Pranav Amin, Director & President- International Business, Alembic Pharmaceuticals, discussed the company‘s quarterly earnings.

    • First launch in Algerian mkt seen in Q1FY16: Alembic Pharma

      First launch in Algerian mkt seen in Q1FY16: Alembic Pharma

      Once this deal is concluded, the company will be renamed as Alembic Mami SPA.

    • Alembic Pharma expects API biz to grow 10% in FY15

      Alembic Pharma expects API biz to grow 10% in FY15

      The growth for the international generics, however, remain muted at about 9 percent due to higher base last year.

    • See 20% EBITDA growth in FY14: Alembic Pharma

      See 20% EBITDA growth in FY14: Alembic Pharma

      In an interview to CNBC-TV18, Amin adds that the company, despite the drug pricing policy, will grow at 15 percent.

    • Not impacted by Ranbaxy's negative news: Alembic Pharma

      Not impacted by Ranbaxy's negative news: Alembic Pharma

      Ranbaxy shares declined a further 2 percent on Wednesday morning after a media report said a prominent hospital in Mumbai had advised doctors to stop using the pharma company's drugs.

    • See 100-120 bps margin improvement in FY14: Alembic Pharma

      See 100-120 bps margin improvement in FY14: Alembic Pharma

      Alembic Pharma is hopeful to increase operating margin by 100-120 basis points in current financial year on the back of strong growth in international and domestic generic business.

    • ANDAs will benefit FY13 and FY14 numbers: Alembic Pharma

      ANDAs will benefit FY13 and FY14 numbers: Alembic Pharma

      Alembic Pharma has announced its third quarter results. Pranav Amin, director of Alembic Pharma says, the revenues have gone up 15%, YoY. He further says, the company so far has filed 41 abbreviated new drug applications (ANDAs). “Over the next couple of years, we should see quite a bit of growth coming in international generic,” he adds.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347